For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of this treatment and the formulated version represents a genuine change. These groundbreaking therapies stabilize the transthyretin protein, preventing its damaging build-up and reducing the burden of the disease . Patients are now expe